Marshall Fordyce - Feb 21, 2025 Form 4 Insider Report for Vera Therapeutics, Inc. (VERA)

Signature
/s/ Joseph R. Young, Attorney-in-Fact
Stock symbol
VERA
Transactions as of
Feb 21, 2025
Transactions value $
-$546,914
Form type
4
Date filed
2/27/2025, 04:05 PM
Previous filing
Feb 20, 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERA Class A Common Stock Sale -$296K -10.6K -4.73% $27.89 214K Feb 21, 2025 Direct F1, F2, F3, F4
transaction VERA Class A Common Stock Sale -$220K -7.98K -3.73% $27.55 206K Feb 26, 2025 Direct F5, F6
transaction VERA Class A Common Stock Sale -$31.2K -1.1K -0.53% $28.32 205K Feb 26, 2025 Direct F5, F7
holding VERA Class A Common Stock 222K Feb 21, 2025 By GRAT
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of three (3) business days, beginning on February 21, 2025 and ending on February 25, 2025.
F2 Pursuant to Rule 16a-3(g)(2) and (3).
F3 Shares sold to cover tax withholding obligations associated with the vesting of RSUs pursuant to an election intended to satisfy the conditions of Rule 10b5-1(c) made by the Reporting Person on August 26, 2022.
F4 The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.37 to $29.80, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F5 The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024.
F6 The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.24 to $28.21, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F7 The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.25 to $28.42, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.